Evidence map›Paper›PMID 38858391›Full record

SynthesisTranslational psychiatry2024

A meta-analysis of the effects of ketamine on suicidal ideation in depression patients.

ZuoYao Shen, DaiQuan Gao, Xue Lv, HongXing Wang, WeiHua Yue

Erratum issued Registry-linked trialAbstract readSystematic ReviewNetwork Meta-Analysis
In one paragraph

Synthesis in Translational psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT07120477 (Esketamine Versus Crisis Response Planning Versus Enhanced Treatment as Usual for Suicide Prevention), which is not on this map. Cited by 16 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07120477 phase4suspendednot on this mapstarted 2026, after this paper: background citation

Esketamine Versus Crisis Response Planning Versus Enhanced Treatment as Usual for Suicide Prevention: A Pragmatic Randomized Trial in a Brazilian Municipality (SAVE)

TypeinterventionalSponsorUniversity of Sao PauloRan2026 to 2029Enrolled468ConditionsSuicide Prevention, Ketamine, Crisis Response PlanArmsIntravenous Esketamine, Crisis Response Planning intervention (structures safety planning)
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Autism, youth suicide, and psychedelics: A review of the 21st century evidence.Journal of the Chinese Medical Association : JCMA · 2024
    Pooled it
  5. Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025
    Trial
  6. Treatment-resistant Depression in the Post-ketamine Era: Unmet Needs beyond Rapid Response.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2026
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

ZuoYao Shen *The First Affiliated Hospital of Xinxiang Medical College Henan, Henan, China.ORCID 0009-0002-3290-0540
DaiQuan Gao *Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.
Xue LvThe First Affiliated Hospital of Xinxiang Medical College Henan, Henan, China.
HongXing WangDepartment of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.ORCID 0000-0002-7942-9330
WeiHua YuePeking University Sixth Hospital, Peking University Institute of Mental Health, Beijing, China. dryue@bjmu.edu.cn.ORCID 0000-0002-1201-8465

Funding

China Primary Health Care Foundation (Primary Health Care Foundation of China) SO.20231226BJ
6 · The paper itself

Abstract

The treatment of suicidal ideation in patients with depression has been a major problem faced by psychiatric and emergency departments, and reasonable drug selection is particularly important. Ketamine has been shown to reduce suicidal ideation rapidly, but the strength of the effect is unclear and there is little evidence-based medical evidence to support this. We systematically searched all articles published on PubMed, Cochrane Library, Web of Science, CNKI and EMBASE. Stata 15 and R 4.1.3 were used for meta-analysis, and odds ratios were calculated in fixed effects or random effects models based on the heterogeneity test results. Our search resulted in 505 articles; we analyzed 14 studies, which included 1,380 participants. The 14 studies included 10 randomized controlled trial (RCT) studies and 4 single-arm studies. Our study suggests that, ketamine has a significant therapeutic effect on suicidal ideation throughout the treatment cycle. We performed network meta-analyses(NMA) and pairwise meta-analyses to compare the efficacy of ketamine in the reduction of suicidal ideation. There was a significant reduction in suicidal ideation within the first day after treatment (NMA ketamine day1 RR = 10.02, 95%CI = 4.24 to 23.68). In repeated treatment, the degree of recovery of suicidal ideation after the last dose was significantly greater than that after the first dose (RR = 0.56, 95%CI = 0.51 to 0.62). Recovery of suicidal ideation was also significantly better in the treatment end point than in the placebo group at the same time point (NMA ketamine day26 RR = 4.29, 95%CI = 1.41 to 13.08). This is the first network meta-analysis to demonstrate the role of ketamine in the alleviation of suicidal ideation. Our network meta-analysis also compared the effects of different drugs at different time points, which was not done in previous studies. This is of great reference significance for future drug research andrational drug use.

Indexed as

KetamineSuicidal IdeationAntidepressive AgentsDepressionDepressive DisorderHumansTreatment OutcomeAntidepressive AgentsKetamine

Identifiers

PMID38858391
PMCPMC11164699

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.